Stockwatch

Date	Sym	Type	Headline
2024-04-25 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
2024-04-24 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
2024-04-16 16:30	UU:HOOK	News Release200	HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2024-04-10 07:01	UU:HOOK	News Release200	HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
2024-03-22 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2024-03-06 07:01	UU:HOOK	News Release200	HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
2024-01-29 08:01	UU:HOOK	News Release200	HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
2024-01-16 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
2023-12-21 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
2023-11-20 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
2023-11-09 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Reports Third Quarter 2023 Financial Results ‚ and Recent Business Highlights
2023-11-03 12:01	UU:HOOK	News Release200	HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
2023-11-02 16:01	UU:HOOK	News Release200	HOOKIPA Pharma to Report Third Quarter 2023 Financial Results ‚ and Recent Business Highlights on November 9, 2023
2023-10-22 06:01	UU:HOOK	News Release200	HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
2023-10-18 07:01	UU:HOOK	News Release200	HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
2023-09-13 08:45	UU:HOOK	News Release200	HOOKIPA Announces Executive Leadership Change
2023-09-12 07:01	UU:HOOK	News Release200	HOOKIPA Announces Grant of Inducement Awards Under ‚ Nasdaq Listing Rule 5635(c)(4)
2023-09-06 07:01	UU:HOOK	News Release200	HOOKIPA Pharma to participate in upcoming investor conferences in September
2023-08-10 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2023-08-03 07:01	UU:HOOK	News Release200	HOOKIPA Pharma to Report Second Quarter 2023 Financial Results ‚ and Recent Business Highlights on August 10, 2023
2023-06-10 05:00	UU:HOOK	News Release200	HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2023-05-31 21:30	UU:HOOK	News Release200	HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
2023-05-31 16:46	UU:HOOK	News Release200	HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
2023-05-11 07:01	UU:HOOK	News Release200	HOOKIPA Pharma Reports First Quarter 2023 Financial Results ‚ and Recent Business Highlights
2023-05-09 07:01	UU:HOOK	News Release200	HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial ‚ of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
2023-05-04 07:02	UU:HOOK	News Release200	HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
2023-05-04 07:01	UU:HOOK	News Release200	HOOKIPA Pharma to Report First Quarter 2023 Financial Results ‚ and Recent Business Highlights on May 11, 2023